A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission Meeting Abstract

  

Authors:	Sabbatini, P.; Chen, L. M.; Lucci, J. A.; Behbakht, K.; Spirtos, N. M.; Muller, C.; Benigno, B. B.; Powell, M. A.; Berry, E.; Tewari, K. S.; Hanjani, P.; Deng, W.; Lankes, H. A.; Aghajanian, C.
Abstract Title:	A phase II randomized, double-blind trial of a polyvalent vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian (EOC), fallopian tube, or peritoneal cancer who are in second or third complete remission
Meeting Title:	52nd Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	34
Issue:	15 Suppl.
Meeting Dates:	2016 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2016-05-20
Start Page:	294s
Language:	English
ACCESSION:	WOS:000404711501193
DOI:	10.1200/JCO.2016.34.15_suppl.5517
PROVIDER:	wos
Notes:	Meeting Abstract: 5517 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/155086